TopoTarget A/S Symbion Fruebjergvej 3 DK 2100 Copenhagen Denmark Tel: +45 39 17 83 92 Fax: +45 39 17 94 92 CVR-nr: 25695771 www.topotarget.com To the Copenhagen Stock Exchange Announcement No. 11-07 / Copenhagen, 19 April 2007 CuraGen and TopoTarget Present New Clinical Results with Belinostat at the Annual Meeting in ASCO and at the conference “2007 Pan Pacific Lymphoma” Copenhagen, 19 April 2007 - TopoTarget A/S (CSE: TOPO) and CuraGen Corporation (NASDAQ: CRGN) announced today that preliminary interim clinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, are expected to be presented at two upcoming major medical meetings. One oral and one poster presentation discussing interim clinical results with belinostat will be made at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being hosted in Chicago, IL, June 2-5, 2007. A poster presentation will also be made at the 2007 Pan Pacific Lymphoma Conference, which is being hosted on the Island of Maui, Hawaii, June 11-15, 2007. 2007 ASCO Annual Meeting - An oral presentation entitled, “A Phase Ib/II study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors,” will be made during the conference's Clinical Science Symposium entitled Breaking the Silence of the Genome: HDAC Inhibitors on Saturday, June 2nd from 2:45 - 4:15 p.m. - A poster presentation entitled, “A Phase I/II study of the safety and anti-cancer activity of IV-administered belinostat (PXD101) plus carboplatin (C) or paclitaxel (P), or both in patients with advanced solid tumors,” will be made during the conference's Developmental Therapeutics: Molecular Therapeutics poster session on Sunday, June 3rd from 8:00 a.m. - 12:00 p.m. 2007 Pan Pacific Lymphoma Conference - A poster presentation entitled, “A Phase II Study of Belinostat (PXD101) in Patients with Recurrent or Refractory Cutaneous or Peripheral T-Cell Lymphoma,” will be on display during the conference beginning at 7:00 a.m., Monday, June 11th through Friday, June 15th. TopoTarget A/S For further information, please contact: Dr. Peter Buhl Jensen Telephone +45 39 17 83 41 Chief Executive Officer Mobile +45 21 60 89 22 Background information About Belinostat (PXD101) Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including 5-FU, car-boplatin, paclitaxel, cis-retinoic acid, azacitidine and Velcade® (bortezomib) for Injec-tion. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes and have been shown to: arrest growth of cancer cells (in-cluding drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resis-tance when used in combination with other anti-cancer agents. Intravenous belinostat is currently being evaluated in multiple clinical trials as a poten-tial treatment for multiple myeloma, T- and B-cell lymphomas, AML, mesothelioma, liver, colorectal, ovarian cancers, either alone or in combination with anti-cancer thera-pies. An oral formulation of belinostat is also being evaluated in a Phase I clinical trial for patients with advanced solid tumors. In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the NCI will sponsor several clinical trials to investigate belinostat for the treatment of various cancers, both as a single-agent and in combination chemotherapy regimens. In May 2005, TopoTarget announced the signing of a Cooperative Research and Development Agreement (CRADA) with the NCI to conduct preclinical and nonclinical studies on belinostat in order to better understand its anti-tumor activity and to provide supporting information for clinical trials. About TopoTarget TopoTarget (OMX - The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA, dedicated to finding ''Answers for Cancer'' and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regula-tors (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclini-cal drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™ is TopoTarget's first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to www.topotarget.com. About CuraGen CuraGen Corporation (NASDAQ: CRGN) is a biopharmaceutical company developing diverse approaches, including novel protein, antibody, antibody-drug conjugate and small molecule therapeutics. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of patients with cancer and inflammatory diseases. CuraGen is focused on bringing velafermin, belinostat and CR011-vcMMAE through clinical development, and maintains a portfolio of earlier-stage compounds that have the potential to treat cancer and inflammatory diseases. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit www.curagen.com. TopoTarget Safe Harbour Statement This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline includ-ing the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expecta-tions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from nonclinical or clinical studies or from other sources; the success of competing products and technolo-gies; technological uncertainty and product development risks; uncertainty of addi-tional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability expo-sure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
CuraGen and TopoTarget Present New Clinical Results with Belinostat at the Annual Meeting in ASCO and at the conference “2007 Pan Pacific Lymphoma”
| Source: Topotarget